目的  构建人IL-2与HBsAg融合基因并转化到BCG中构建重组BCG（recombinant BCG，rBCG），为制备治疗和预防乙型肝炎和结核病的二联疫苗奠定基础。方法  以IL-2 pMalLP质粒和HBsAg pMalLP质粒为模板，设计引物，利用PCR技术扩增HBsAg和IL-2基因，进行重叠PCR获得融合基因IL-2-HBsAg并纯化，将融合基因克隆至穿梭表达载体pMV261上得到重组质粒，然后电转化导入BCG感受态细胞，以蛋白质印迹法检测融合基因在rBCG中的表达。结果  通过重叠PCR的方法成功获得IL-2-HBsAg融合基因，将融合基因成功插入穿梭表达载体，rBCG能分泌表达融合蛋白。结论 构建人IL-2与 HBsAg融合基因重组质粒并导入BCG，获得了稳定表达融合蛋白的rBCG。

Objective  To construct the fusion gene of human IL-2 and HBsAg and transform into BCG for expression, laying foundation for preparation of double vaccine for prevention and treatment of hepatitis B and tuberculosis. Methods  Using IL-2 pMalLP and HBsAg  pMalLP as templates, primers were designed.HBsAg and IL-2 genes were amplified by PCR , and then the fusion gene IL-2-HBsAg was obtained by overlapping PCR and purified. The fusion gene was cloned on the shuttle expression vector pMV261 to obtain the recombinant plasmid, and then the fusion gene was transformed into BCG sensitive cells by electricity, and the expression of the fusion gene in recombinant BCG（rBCG） was detected by Western blot. Results  IL-2 (435 bp) gene and HBsAg (681 bp) gene were amplified by PCR, and IL-2-HBsAg (1 179 bp) fusion gene was amplified by overlapping PCR. The fusion gene was successfully inserted into the shuttle expression vector. The fusion protein was detected in rBCG. Conclusion  The recombinant plasmid of human IL-2 and HBsAg fusion gene is successfully constructed and introduced into BCG to obtain rBCG which can stably express the fusion protein.